BACKGROUND: Radioembolization (RE) with yttrium-90 (90Y) resin microspheres yields heterogeneous response rates in with primary or secondary liver cancer. Radiation-induced liver disease (RILD) is a potentially life-threatening complication with higher prevalence in cirrhotics or patients exposed to previous chemotherapies. Advances in RILD prevention may help increasing tolerable radiation doses to improve patient outcomes. This study aimed to evaluate the impact of post-therapeutic RILD-prophylaxis in a cohort of intensely pretreated liver metastatic breast cancer patients; Methods: Ninety-three patients with liver metastases of breast cancer received RE between 2007 and 2016. All Patients received RILD prophylaxis for 8 weeks post-RE. From January 2014, RILD prophylaxis was changed from ursodeoxycholic acid (UDCA) and prednisolone (standard prophylaxis [SP]; n = 59) to pentoxifylline (PTX), UDCA and low-dose low molecular weight heparin (LMWH) (modified prophylaxis (MP); n = 34). The primary endpoint was toxicity including symptoms of RILD; Results: Dose exposure of normal liver parenchyma was higher in the modified vs. standard prophylaxis group (47.2 Gy (17.8-86.8) vs. 40.2 Gy (12.5-83.5), p = 0.017). All grade RILD events (mild: bilirubin ≥ 21 µmol/L (but <30 μmol/L); severe: (bilirubin ≥ 30 µmol/L and ascites)) were observed more frequently in the SP group than in the MP group, albeit without significance (7/59 vs. 1/34; p = 0.140). Severe RILD occurred in the SP group only (n = 2; p > 0.1). ALBI grade increased in 16.7% patients in the MP and in 27.1% patients in the SP group, respectively (group difference not significant); Conclusions: At established dose levels, mild or severe RILD events proved rare in our cohort. RILD prophylaxis with PTX, UDCA and LMWH appears to have an independent positive impact on OS in patients with metastatic breast cancer and may reduce the frequency and severity of RILD. Results of this study as well as pathophysiological considerations warrant further investigations of RILD prophylaxis presumably targeting combinations of anticoagulation (MP) and antiinflammation (SP) to increase dose prescriptions in radioembolization.
BACKGROUND: Radioembolization (RE) with yttrium-90 (90Y) resin microspheres yields heterogeneous response rates in with primary or secondary liver cancer. Radiation-induced liver disease (RILD) is a potentially life-threatening complication with higher prevalence in cirrhotics or patients exposed to previous chemotherapies. Advances in RILD prevention may help increasing tolerable radiation doses to improve patient outcomes. This study aimed to evaluate the impact of post-therapeutic RILD-prophylaxis in a cohort of intensely pretreated liver metastatic breast cancerpatients; Methods: Ninety-three patients with liver metastases of breast cancerreceived RE between 2007 and 2016. All Patientsreceived RILD prophylaxis for 8 weeks post-RE. From January 2014, RILD prophylaxis was changed from ursodeoxycholic acid (UDCA) and prednisolone (standard prophylaxis [SP]; n = 59) to pentoxifylline (PTX), UDCA and low-dose low molecular weight heparin (LMWH) (modified prophylaxis (MP); n = 34). The primary endpoint was toxicity including symptoms of RILD; Results: Dose exposure of normal liver parenchyma was higher in the modified vs. standard prophylaxis group (47.2 Gy (17.8-86.8) vs. 40.2 Gy (12.5-83.5), p = 0.017). All grade RILD events (mild: bilirubin ≥ 21 µmol/L (but <30 μmol/L); severe: (bilirubin ≥ 30 µmol/L and ascites)) were observed more frequently in the SP group than in the MP group, albeit without significance (7/59 vs. 1/34; p = 0.140). Severe RILD occurred in the SP group only (n = 2; p > 0.1). ALBI grade increased in 16.7% patients in the MP and in 27.1% patients in the SP group, respectively (group difference not significant); Conclusions: At established dose levels, mild or severe RILD events proved rare in our cohort. RILD prophylaxis with PTX, UDCA and LMWH appears to have an independent positive impact on OS in patients with metastatic breast cancer and may reduce the frequency and severity of RILD. Results of this study as well as pathophysiological considerations warrant further investigations of RILD prophylaxis presumably targeting combinations of anticoagulation (MP) and antiinflammation (SP) to increase dose prescriptions in radioembolization.
Authors: Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy Journal: Gastroenterology Date: 2010-10-30 Impact factor: 22.682
Authors: Jens Ricke; Heinz Josef Klümpen; Holger Amthauer; Irene Bargellini; Peter Bartenstein; Enrico N de Toni; Antonio Gasbarrini; Maciej Pech; Markus Peck-Radosavljevic; Peter Popovič; Olivier Rosmorduc; Eckart Schott; Max Seidensticker; Chris Verslype; Bruno Sangro; Peter Malfertheiner Journal: J Hepatol Date: 2019-08-14 Impact factor: 25.083
Authors: Pierce K H Chow; Mihir Gandhi; Say-Beng Tan; Maung Win Khin; Ariunaa Khasbazar; Janus Ong; Su Pin Choo; Peng Chung Cheow; Chanisa Chotipanich; Kieron Lim; Laurentius A Lesmana; Tjakra W Manuaba; Boon Koon Yoong; Aloysius Raj; Chiong Soon Law; Ian H Y Cua; Rolley R Lobo; Catherine S C Teh; Yun Hwan Kim; Yun Won Jong; Ho-Seong Han; Si-Hyun Bae; Hyun-Ki Yoon; Rheun-Chuan Lee; Chien-Fu Hung; Cheng-Yuan Peng; Po-Chin Liang; Adam Bartlett; Kenneth Y Y Kok; Choon-Hua Thng; Albert Su-Chong Low; Anthony S W Goh; Kiang Hiong Tay; Richard H G Lo; Brian K P Goh; David C E Ng; Ganesh Lekurwale; Wei Ming Liew; Val Gebski; Kenneth S W Mak; Khee Chee Soo Journal: J Clin Oncol Date: 2018-03-02 Impact factor: 44.544
Authors: Bernard Cheng; Ila Sethi; Neena Davisson; David Brandon; Bruce Barron; James Galt; Zachary Bercu; David M Schuster; Nima Kokabi Journal: Nucl Med Commun Date: 2021-04-01 Impact factor: 1.690
Authors: Konrad Mohnike; Ingo G Steffen; Max Seidensticker; Peter Hass; Robert Damm; Nils Peters; Ricarda Seidensticker; Kerstin Schütte; Jörg Arend; Jan Bornschein; Tina Streitparth; Christian Wybranski; Gero Wieners; Patrick Stübs; Peter Malfertheiner; Maciej Pech; Jens Ricke Journal: Cardiovasc Intervent Radiol Date: 2018-11-28 Impact factor: 2.740
Authors: Fourat Ridouani; Mohamed M Soliman; Ryan W England; Meier Hsu; Chaya S Moskowitz; Raphael Doustaly; Constantinos T Sofocleous; F Edward Boas; Hooman Yarmohammadi; Amy R Deipolyi Journal: Eur J Radiol Date: 2021-01-12 Impact factor: 3.528
Authors: L Wyld; E Gutteridge; S E Pinder; J J James; S Y Chan; K L Cheung; J F R Robertson; A J Evans Journal: Br J Cancer Date: 2003-07-21 Impact factor: 7.640